EA200971093A1 - Терапевтические композиции и их применение - Google Patents

Терапевтические композиции и их применение

Info

Publication number
EA200971093A1
EA200971093A1 EA200971093A EA200971093A EA200971093A1 EA 200971093 A1 EA200971093 A1 EA 200971093A1 EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A1 EA200971093 A1 EA 200971093A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
acceptable salt
application
therapeutic compositions
compositions
Prior art date
Application number
EA200971093A
Other languages
English (en)
Russian (ru)
Inventor
Брайан П. Кирни
Анита А. Матиас
Сринивасан Раманатан
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA200971093A1 publication Critical patent/EA200971093A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200971093A 2007-06-29 2008-06-26 Терапевтические композиции и их применение EA200971093A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94730607P 2007-06-29 2007-06-29
US4092008P 2008-03-31 2008-03-31
PCT/US2008/068339 WO2009006199A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
EA200971093A1 true EA200971093A1 (ru) 2010-08-30

Family

ID=39831893

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971093A EA200971093A1 (ru) 2007-06-29 2008-06-26 Терапевтические композиции и их применение

Country Status (19)

Country Link
US (4) US20090093467A1 (cg-RX-API-DMAC7.html)
EP (1) EP2167088A1 (cg-RX-API-DMAC7.html)
JP (3) JP5547066B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100040892A (cg-RX-API-DMAC7.html)
CN (2) CN101686972B (cg-RX-API-DMAC7.html)
AP (1) AP2965A (cg-RX-API-DMAC7.html)
AR (1) AR067183A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008270630B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813000A2 (cg-RX-API-DMAC7.html)
CA (1) CA2692101A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251237A2 (cg-RX-API-DMAC7.html)
EA (1) EA200971093A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP109897A (cg-RX-API-DMAC7.html)
IL (1) IL202744A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013829A (cg-RX-API-DMAC7.html)
NZ (1) NZ582086A (cg-RX-API-DMAC7.html)
SG (1) SG182229A1 (cg-RX-API-DMAC7.html)
TW (1) TW200914011A (cg-RX-API-DMAC7.html)
WO (1) WO2009006199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219243A1 (en) * 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
KR101477822B1 (ko) 2006-07-07 2015-01-02 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
ES2536923T3 (es) 2006-09-12 2015-05-29 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa del VIH
PT3150586T (pt) * 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
US20130203759A1 (en) * 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
US20130274254A1 (en) * 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2880017B1 (en) 2012-08-03 2016-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
NO2865735T3 (cg-RX-API-DMAC7.html) 2013-07-12 2018-07-21
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
NO2717902T3 (cg-RX-API-DMAC7.html) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6544540B2 (en) * 1998-07-29 2003-04-08 Syngenta Limited Base-triggered release microcapsules
US7176220B2 (en) * 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
US20070219243A1 (en) * 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
KR101477822B1 (ko) * 2006-07-07 2015-01-02 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
ES2536923T3 (es) * 2006-09-12 2015-05-29 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa del VIH
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EA201591353A1 (ru) * 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
BRPI0813000A2 (pt) 2014-12-23
US20100331331A1 (en) 2010-12-30
CN101686972B (zh) 2013-08-14
US20140343063A1 (en) 2014-11-20
US20090093467A1 (en) 2009-04-09
JP5547066B2 (ja) 2014-07-09
IL202744A0 (en) 2010-06-30
WO2009006199A1 (en) 2009-01-08
AP2965A (en) 2014-09-30
ECSP109897A (es) 2010-03-31
CN103480000A (zh) 2014-01-01
JP5769763B2 (ja) 2015-08-26
CN101686972A (zh) 2010-03-31
JP2013199495A (ja) 2013-10-03
US20170136001A1 (en) 2017-05-18
KR20100040892A (ko) 2010-04-21
MX2009013829A (es) 2010-03-10
AP2009005074A0 (en) 2009-12-31
TW200914011A (en) 2009-04-01
AU2008270630B2 (en) 2014-01-16
JP2015143278A (ja) 2015-08-06
AU2008270630A1 (en) 2009-01-08
AR067183A1 (es) 2009-09-30
CO6251237A2 (es) 2011-02-21
EP2167088A1 (en) 2010-03-31
NZ582086A (en) 2012-07-27
JP2010532372A (ja) 2010-10-07
SG182229A1 (en) 2012-07-30
CA2692101A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
EA200971096A1 (ru) Терапевтические композиции и их применение
MX2009013829A (es) Composiciones terapeuticas y su uso.
EA201291301A1 (ru) Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
EA201391395A1 (ru) Терапевтические соединения
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
WO2014134566A3 (en) Amide compounds for the treatment of hiv
EA201270247A1 (ru) Способы применения с-мет-модуляторов
EA200901241A1 (ru) Соединения для лечения гепатита с
PH12013500011A1 (en) Napht-2-ylacetic acid derivatives to treat aids
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
EA201290632A1 (ru) Производные бетулина
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201290416A1 (ru) Новые спиропиперидиновые соединения
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201190293A1 (ru) Пролекарства триптолида
EA201270275A1 (ru) Кристаллическое соединение пиридазина
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor